Pharmacogenomics, Precision Medicine and Molecular Epidemiology

Code:

MOM23_02

Acronym:

MOM23_02

Keywords
Classification	Keyword
OFICIAL	Medical and Molecular Oncology

Instance: 2023/2024 - SP

Active?	Yes
Responsible unit:	Departamento de Biomedicina
Course/CS Responsible:	Molecular Medicine and Oncology

Cycles of Study/Courses

Acronym	No. of Students	Study Plan	Curricular Years	Credits UCN	Credits ECTS	Contact hours	Total Time
MOM	3	Current Studies Plan	1	-	3	21	81

Teaching language

Suitable for English-speaking students

Objectives

General objective:

To present a current vision of Pharmacogenomics and Precision Medicine and their role in Modern Medicine, as vectors for the individualization of treatments or chemoprevention, thus changing behaviors and encouraging the practice of evidence-based medicine.

Particular objectives:

Theoretical review and discussion of current knowledge, with particular emphasis on its importance for developing the skills of health professionals and understanding the appropriate strategies for Personalized Medicine.

Knowledge of the impact of new technologies in Precision Medicine and Pharmacogenomics, as promoters of better diagnosis, earlier treatment and earlier disease prevention, taking into account individual variability: genetics, lifestyles and the environment.

Learning outcomes and competences

Students should be able to recognize up-to-date examples of the application of Pharmacogenomics to Personalized and Precision Medicine.

The use of examples with clinical relevance for humans and focused on the syllabus, prepares students for this professional challenge. Furthermore, in the case of doctors, pharmacists or other health professionals, alerts will be generated regarding new advances in the area and the scientific qualification for a scientifically based critical attitude.

The students will be encouraged to pay attention to conditions that may affect the effectiveness and toxicity of therapeutic procedures in order to minimize the associated risks during intervention.

Working method

Presencial

Program

Introduction to Pharmacogenomics and Precision Medicine: on the route from Molecular Biology to Personalized Medicine

- Importance of Pharmacogenomics and the Concept of Precision Medicine in the Teaching of Biomedical Sciences and its evolution into new areas such as Molecular Epidemiology and Ecogenetics.

- Molecular Biology, Ecogenetics and Epidemiology. Integrative Molecular Epidemiology: From Risk Assessment to Outcome Prediction

- Biopathology, Toxicity and Molecular Medicine

- Basics of Pharmacokinetics and Pharmacodynamics

- Biotransformation and Phase I and II Metabolism

- Genetic Polymorphisms and Pharmacogenomics

- Phase I and II Metabolism and Genetic Polymorphisms

- Other Genetic Models in Pharmacogenomics

- Pharmacogenomics in Preventive Medicine

- Primer in Precision Medicine

- Pharmacogenomics in Oncology and Other Pathologies

- Pharmacogenomics and the development of new therapeutic targets

- Therapeutic and prognostic models: implications for pharmacogenomics

- Vírus, Molecular Epidemiology and Therapeutic Strategies

-Informatics-based approaches and biomedical technologies for Precision Medicine and Pharmacogenomics. 

Mandatory literature

Yui-Wing Francis Lam Larisa Cavallari; Pharmacogenomics
Bienfait K, Chhibber A, Marshall JC, Armstrong M, Cox C, Shaw PM, Paulding C; Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG), Hum Genet. 2021 Jun 3. , 2021 (doi: 10.1007/s00439-021-02282-3)
Saulsberry L, Olopade OI; Precision oncology: Directing genomics and pharmacogenomics toward reducing cancer inequities, Cancer Cell. 2021 Jun 14;39(6):730-733, 2021 (doi: 10.1016/j.ccell.2021.04.013)
Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, Williams A, Bhairo S, Voegtline T, Davis H, Shekhar A, Kurian SM, Niculescu AB; Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs, Mol Psychiatry. 2021 Apr 8. (doi: 10.1038/s41380-021-01061-w)
Kim JA, Ceccarelli R, Lu CY; Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020), J Pers Med. 2021 Mar 4;11(3):179, 2021 (doi: 10.3390/jpm11030179)
Wong M, Previde P, Cole J, Thomas B, Laxmeshwar N, Mallory E, Lever J, Petkovic D, Altman RB, Kulkarni A; Search and visualization of gene-drug-disease interactions for pharmacogenomics and precision medicine research using GeneDive., J Biomed Inform. 2021 May;117:103732., 2021 (doi: 10.1016/j.jbi.2021.103732)
Dias F, Almeida C, Teixeira AL, Morais M, Medeiros R; Related microRNAs as Potential New Therapeutic Agents against Colorectal Cancer Progression, Biomedicines. 2021 Feb 16;9(2):195, 2021 (doi: 10.3390/biomedicines9020195)
Tavares V, Pinto R, Assis J, Coelho S, Brandão M, Alves S, Pereira D, Medeiros R; Implications of venous thromboembolism GWAS reported genetic makeup in the clinical outcome of ovarian cancer patients, Pharmacogenomics J. 2021 Apr;21(2):222-232. , 2021 (doi: 10.1038/s41397-020-00201-9)
Afonso A, Silva J, Lopes AR, Coelho S, Patrão AS, Rosinha A, Carneiro F, Pinto AR, Maurício MJ, Medeiros R; YB-1 variant and androgen receptor axis- targeted agents in metastatic castration-resistant prostate cancer patients, Pharmacogenomics. 2020 Aug;21(13):919-928., 2020 (doi: 10.2217/pgs-2020-0008)
Dias F, Teixeira AL, Nogueira I, Morais M, Maia J, Bodo C, Ferreira M, Vieira I, Silva J, Lobo J, Sequeira JP, Maurício J, Oliveira J, Palmeira C, Martins G, Kok K, Costa-Silva B, Medeiros R; Plasma Extracellular Vesicle- Derived TIMP-1 mRNA as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Pilot Study, Int J Mol Sci. 2020 Jun 29;21(13):4624. (doi: 10.3390/ijms21134624.)
Ferreira M, Freitas-Silva M, Assis J, Pinto R, Nunes JP, Medeiros R; he emergent phenomenon of aspirin resistance: insights from genetic association studies, Pharmacogenomics. 2020 Jan;21(2):125-140, 2020 (doi: 10.2217/pgs-2019-0133)
Pinto R, Assis J, Nogueira A, Pereira C, Coelho S, Brandão M, Dias J, Alves S, Pereira D, Medeiros R; Pharmacogenomics in epithelial ovarian cancer first- line treatment outcome: validation of GWAS-associated NRG3 rs1649942 and BRE rs7572644 variants in an independent cohort., Pharmacogenomics J. 2019 Feb;19(1):25-32, 2019 (doi: 10.1038/s41397-018-0056-y)
Patrão AS, Dias F, Teixeira AL, Maurício J, Medeiros R; XPO5 genetic polymorphisms in cancer risk and prognosis, Pharmacogenomics. 2018 Jun 1;19(9):799-808., 2018 (doi: 10.2217/pgs-2018-0018)

Teaching methods and learning activities

Form of educational performance: Lecture with the presentation and discussion of relevant theoretical concepts in the classroom, self-study orientation of students by consulting annotated bibliography.
Seminars, Brainstorm on pertinent issues related to the matter exposed in the classroom. Written Evaluation.

Evaluation Type

Distributed evaluation with final exam

Assessment Components

Designation	Weight (%)
Exame	100,00
Total:	100,00

Amount of time allocated to each course unit

Designation	Time (hours)
Estudo autónomo	58,00
Frequência das aulas	23,00
Total:	81,00

Eligibility for exams

Presence in a minimum of 75% of classes.

Calculation formula of final grade

without formula.

Examinations or Special Assignments

To be evaluated